Algernon Pharmaceuticals announces increase to private placement

Algernon Pharmaceuticals announces an increase to its non-brokered private placement, previously announced on July 11, 2024, from gross proceeds of $250,000 to $408,000 of units at an issue price of $0.12 per Unit. Each Unit will consist of one Class A common share in the capital of the Company and one Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.24 per Warrant Share for a period of 2 years from the date of issuance subject to acceleration of the Expiry Date as described below. The Offering is expected to close on August 1, 2024. The Warrants are subject to accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.36 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating the Expiry Date of the Warrants to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice. Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period. The Company may pay cash finder’s fees and finders warrants to eligible finders, up to eight percent of the proceeds raised and units issued for investors introduced to the Company by the eligible finder. The Company will use the proceeds of the private placement for working capital purposes.